Precigen, Inc.

Precigen, Inc.

Precigen, Inc.

Overview
Date Founded

2017

Headquarters

20374 Seneca Meadows Parkway Germantown MD 20876

Type of Company

Public

Employees (Worldwide)

194

Industries

Biotechnology
Pharmaceuticals
Medical Support Services

Company Description

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Trans Ova segment includes provides advanced reproductive technologies. The Human Biotherapeutics segment accelerated recognition of previously deferred revenue upon the mutual termination of a collaboration with Castle Creek in 2020. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Contact Data
Trying to get in touch with decision makers at Precigen, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Legal Officer

Head, Intrexon Health

Head of Business Development

Senior Vice President-Intellectual Property Affairs

President, Chief Executive Officer & Director

General Counsel

General Manager

Chief Executive Officer, Mbp Titan LLC

Head-Research

Board of Directors

Founder at Third Security LLC

Chief Executive Officer & Executive Director at Lupin Ltd.

Chairman at Caret Group LLC

Co-Founder at Panic, Inc.

Managing Director at Cultivian Sandbox Venture Management LLC

President, Chief Executive Officer & Director at Precigen, Inc.

Paths to Precigen, Inc.
Potential Connections via
Relationship Science
You
Precigen, Inc.
Owners & Shareholders
Details Hidden

MVP offers clients a value-driven, consistent, research intensive investment process. The firm strives to outperform their benchmarks over the long-term. They seek to provide their client accounts with long-term capital appreciation by actively selecting securities they believe are trading at a discount to intrinsic value.

Details Hidden

MSD Partners is a fundamental value investor which seeks to make investments that consistently generate attractive risk-adjusted returns over the long-term. The firm utilizes a multi-disciplinary framework of analysis to evaluate investment opportunities across the globe in the debt and equity of public and private companies, real estate and other asset classes.

Details Hidden

FW’s investment philosophy is fundamentally oriented, based on the belief that over time the investment process is rational. The style is oriented toward GARP with a value component added while using all-cap universe. The firm uses disciplined guidelines in both the purchase and sale of securities.

Recent Transactions
Details Hidden

Precigen, Inc. issued USD Common Stock

Details Hidden

Darling Ingredients, Inc. purchases EnviroFlight LLC from Precigen, Inc.

Details Hidden

Third Security LLC purchases AquaBounty Technologies, Inc. from Precigen, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onPrecigen, Inc. issued USD Common Stock

Underwriter

Advised onPrecigen, Inc. issued USD Common Stock

Auditor

Advised onPrecigen, Inc. issued USD Common Stock

Legal Advisor

Advised onPrecigen, Inc. issued USD Common Stock

Legal Advisor

Advised onPrecigen, Inc. issued USD Common Stock

Managing Director Healthcare Investment Banking

Advised onPrecigen, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Consultant

Former Director at National Cancer Institute

Clients

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Castle Creek Pharmaceuticals LLC operates as a biopharmaceutical company. It develops drugs for genetic rare diseases. It focuses on developing and commercializing new treatment options for patients with the unmet medical need. The company was founded by Michael Derby and Jeffrey S. Aronin in 2015 and is headquartered in Parsippany, NJ.

We are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets. Within oral health we are commercializing our patented probiotic blend, ProBiora3® specifically formulated for oral health both under our branded Evora line and in private label configurations. Currently we have sales or contracts to sell these products in over 15 countries around the world. Our recent partnership with Intrexon in the field of Lantibiotics, a largely overlooked class of extremely potent gram-positive antibiotics, will help us to develop our pharmaceutical product candidate, MU1140-S™ and additional antibiotics from the Lantibiotic class for therapeutic use. The focus on the probiotic area will be to grow sales through a variety of channels including internet sales and the professional channel (dentists and hygienists) as well as through private label and bulk sales of our patented ProBiora3 blend. We intend to look for opportunities to expand our health claims for these products through a range of clinical studies. We are also looking at novel and convenient new delivery systems for our probiotics, which we plan to commercialize in the near future. In 2011 we received the Frost and Sullivan Award for excellence in probiotics. This was a competitive award that placed us as a leader in the probiotic space

Key Stats and Financials As of 2020
Market Capitalization
$1.35B
Total Enterprise Value
$1.79B
Earnings Per Share
$-1.02
Revenue
$103M
Net Profit
$-171M
EBITDAMargin
-68.47%
Enterprise Value / Sales
17.31x
TEVNet Income
-10.43x
Debt TEV
0.1x
Total Debt
$182M
Total Equity
$67.2M
EBITDA
$-70.6M
Three Year Compounded Annual Growth Rate Of Revenue
-23.56%
Non-Profit Donations & Grants
$10K - $100K
2019
$10K - $100K
2018
$10K - $25K
2017
Investors
Details Hidden

Founder at Third Security LLC

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Details Hidden

Founder at Precigen, Inc.

Suppliers
University of Texas - MD Anderson Cancer Center Medical Support Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Precigen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Precigen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Precigen, Inc..